Danaher NYSE: DHR is focusing on commercial execution, innovation and acquisitions as it seeks faster core growth and market-share gains, company leader Julie said during a discussion with Tycho Peterson of the Life Science team.
Julie, who was identified only by her first name in the transcript, said Danaher wants to make it easier for customers to buy across its operating companies. The company is adding a key-account layer to coordinate those relationships, she said, adding that the approach has already created several hundred million dollars of incremental opportunity in diagnostics.
She also reaffirmed a preliminary starting point of 4% to 5% core growth excluding respiratory products for next year. Danaher plans to provide a more quantified outlook in January after completing its usual planning process, she said.
Innovation and Diagnostics
Danaher spends about $1.7 billion annually on innovation, and Julie said the company considers that the right amount. Its priority is to direct research and development spending toward the initiatives with the greatest growth potential, rather than increase or reduce the total budget.
In diagnostics, she said, a sharper focus on innovation priorities has increased forecast growth from innovation by 80%. She pointed to blood-based biomarker testing for Alzheimer’s disease, oncology, artificial intelligence drug discovery and process intensification in advanced modalities as opportunities.
Julie said Danaher’s diagnostics business has grown to $11 billion from $6 billion when she joined the company in 2017, with operating profit tripling. She cited Leica Biosystems as an example of the company’s approach: improved account planning and commercial execution helped lift its growth rate from the mid-single digits to the high single digits.
Leica has also invested in companion diagnostics and pharma services, building a pipeline of deals for quantitative companion diagnostics. Those projects will take time to have a material financial impact because they must proceed through development, she said.
Acquisitions Remain a Priority
Julie said mergers and acquisitions remain Danaher’s top capital-deployment priority. The company is looking for businesses with a credible path to differentiated growth that can strengthen its platforms and benefit from the Danaher Business System, she said.
Danaher has deployed more than $11 billion in capital this year, Julie said, citing Masimo and StatLab as recent acquisitions. She said the deals are expected to generate strong high-single-digit returns on invested capital by year five or earlier. Danaher will also consider share repurchases opportunistically and remains committed to its dividend.
Asked about lessons from earlier deals, Julie said the company misjudged the timing of cell and gene therapy adoption in the case of Aldevron. The lesson, she said, was to examine a fuller range of possible adoption curves for new technologies and products.
AI and Bioprocessing
Danaher sees opportunities to use AI both in customer products and internally, Julie said. Its first autonomous laboratory for affinity reagents connects AI with physical experiments in a closed loop, producing an eightfold productivity benefit, she said. Danaher teams are also shortening some research and development schedules by 25% to 40% through molecular design and process improvements.
In bioprocessing, Julie said she expects Cytiva to be a long-term, high-single-digit growth business. She cited demand for monoclonal antibodies and biosimilars, advanced therapies and the reshoring of production as potential drivers.
Danaher estimates reshoring will create $1 billion in incremental market opportunity for bioprocessing equipment. Some orders for existing facilities are already coming through, while larger new-facility projects are generally still in discussions, she said. The company expects the opportunity to become more material starting in 2028.
About Danaher (NYSE:DHR)
Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company's businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.